NML confirms MonkeyPox is of the same category
Very interesting. Confirmed by NML.
MonkeyPox falls into the same categories (lipid enveloped viruses) than the viruses (influenza, Zika, herpes, BSL-2 viruses SARS-2-COV (coronavirus (BSL-3)) against which TLD1433 has been proven effective to destroy.
So it's fair to think that with this MonkeyPox virus being on the verge of being declared .......... that the NML has/will probably try to see if our Theralase® anti-viral platform technology can also be effective in the destruction of this virus. That would make our platform even more versatile by being applicable to a wide range of enveloped viruses.
Dr. Arkady Mandel, M.D., Ph.D., D.Sc., Interim Chief Executive Officer and Chief Scientific Officer, Theralase® stated, “The latest preliminary results by Dr. Kobasa and Dr. Coombs, demonstrates that the Theralase® vaccine may potentially be effective as a Canadian-made wholly-inactivated vaccine to prevent individuals from contracting COVID-19 in the future and warrants further research to confirm the findings. The research also demonstrates that the Theralase® platform is extremely versatile, with an ability to be applicable to a wide range of enveloped viruses. This would allow the Company to tailor the vaccine to be potentially effective against contracting various viruses (existing and/or new) and their associated variants. Based on this encouraging data, the Company intends to move forward in the research, development and commercialization of the Theralase® COVID-19 vaccine, subject to the required regulatory approval.”